نتایج جستجو برای: ژن های tp53

تعداد نتایج: 489791  

Journal: :Cancer research 2000
E M Berns J A Foekens R Vossen M P Look P Devilee S C Henzen-Logmans I L van Staveren W L van Putten M Inganäs M E Meijer-van Gelder C Cornelisse C J Claassen H Portengen B Bakker J G Klijn

TP53 has been implicated in regulation of the cell cycle, DNA repair, and apoptosis. We studied, in primary breast tumors through direct cDNA sequencing of exons 2-11, whether TP53 gene mutations can predict response in patients with advanced disease to either first-line tamoxifen therapy (202 patients, of whom 55% responded) or up-front (poly)chemotherapy (41 patients, of whom 46% responded). ...

Journal: :Human mutation 2005
Thierry Soussi Shunsuke Kato Pierre P Levy Chikashi Ishioka

TP53 alteration is the most frequent genetic alteration found in human cancers. To date, more than 15,000 tumors with TP53 mutations have been published, leading to the description of more than 1,500 different TP53 mutants (http://p53.curie.fr). The frequency of these mutants is highly heterogeneous, with 11 hotspot mutants found more than 100 times, whereas 306 mutants have been reported only ...

2016
Martin Köbel Anna M Piskorz Sandra Lee Shuhong Lui Cecile LePage Francesco Marass Nitzan Rosenfeld Anne‐Marie Mes Masson James D Brenton

TP53 mutations are ubiquitous in high-grade serous ovarian carcinomas (HGSOC), and the presence of TP53 mutation discriminates between high and low-grade serous carcinomas and is now an important biomarker for clinical trials targeting mutant p53. p53 immunohistochemistry (IHC) is widely used as a surrogate for TP53 mutation but its accuracy has not been established. The objective of this study...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2002
Aurelia Peraud Friedrich W Kreth Otmar D Wiestler Paul Kleihues Hans-Jürgen Reulen

PURPOSE The purpose of this study was to analyze retrospectively timing, frequency, and prognostic impact of TP53 mutations and P53 protein accumulation in supratentorial WHO grade II astrocytomas and oligoastrocytomas of adult patients. EXPERIMENTAL DESIGN We included 159 consecutively treated patients (1991-1998), and each tumor was screened for TP53 mutations and P53 protein overexpression...

Journal: :Cancer research 2009
Henne Holstege Simon A Joosse Conny Th M van Oostrom Petra M Nederlof Annemieke de Vries Jos Jonkers

Approximately half of all hereditary breast cancers are compromised in their DNA repair mechanisms due to loss of BRCA1 or BRCA2 function. Previous research has found a strong correlation between BRCA mutation and TP53 mutation. However, TP53 mutation status is often indirectly assessed by immunohistochemical staining of accumulated p53 protein. We sequenced TP53 exons 2 to 9 in 21 BRCA1-relate...

2016
Sarah A Hansen Marcia L Hart Susheel Busi Taybor Parker Angela Goerndt Kevin Jones James M Amos-Landgraf Elizabeth C Bryda

Somatic mutations in the Tp53 tumor suppressor gene are the most commonly seen genetic alterations in cancer, and germline mutations in Tp53 predispose individuals to a variety of early-onset cancers. Development of appropriate translational animal models that carry mutations in Tp53 and recapitulate human disease are important for drug discovery, biomarker development and disease modeling. Cur...

Journal: :Blood 2008
Ken H Young Karen Leroy Michael B Møller Gisele W B Colleoni Margarita Sánchez-Beato Fábio R Kerbauy Corinne Haioun Jens C Eickhoff Allen H Young Philippe Gaulard Miguel A Piris Terry D Oberley William M Rehrauer Brad S Kahl James S Malter Elias Campo Jan Delabie Randy D Gascoyne Andreas Rosenwald Lisa Rimsza James Huang Rita M Braziel Elaine S Jaffe Wyndham H Wilson Louis M Staudt Julie M Vose Wing C Chan Dennis D Weisenburger Timothy C Greiner

The purpose of this study is to correlate the presence of TP53 gene mutations with the clinical outcome of a cohort of patients with diffuse large B-cell lymphoma (DLBCL) assembled from 12 medical centers. TP53 mutations were identified in 102 of 477 patients, and the overall survival (OS) of patients with TP53 mutations was significantly worse than those with wild-type TP53 (P < .001). However...

2014
Cong-Jun Li Robert W Li

Butyrate affects cell proliferation, differentiation, and motility. Butyrate inhibits histone deacetylase (HDAC) activities and induces cell-cycle arrest and apoptosis. TP53 is one of the most active upstream regulators discovered by ingenuity pathways analysis (IPA) in our RNA-sequencing data set. TP53 signaling pathway plays key role in many cellular processes. TP53 pathway and their involvem...

Journal: :Acta dermatovenerologica Croatica : ADC 2005
Andrija Stanimirović Hrvoje Cupić Berislav Bosnjak Davor Tomas Bozo Kruslin Mladen Belicza

The incidence and prevalence of premalignant and malignant skin lesions including squamous cell carcinoma (SCC) of the skin are increasing worldwide. The aim of the study was to determine TP53, Bcl-2 and growth hormone receptor (GHR) expression in SCC and to investigate relative importance of these proto-oncogenes in its biological behavior. Expression of TP53, Bcl-2 and GHR was determined by i...

2012
Mohamed Jemaà Ilio Vitale Oliver Kepp Francesco Berardinelli Lorenzo Galluzzi Laura Senovilla Guillermo Mariño Shoaib Ahmad Malik Santiago Rello-Varona Delphine Lissa Antonio Antoccia Maximilien Tailler Frederic Schlemmer Francis Harper Gérard Pierron Maria Castedo Guido Kroemer

The genetic or functional inactivation of p53 is highly prevalent in human cancers. Using high-content videomicroscopy based on fluorescent TP53(+/+) and TP53(-/-) human colon carcinoma cells, we discovered that SP600125, a broad-spectrum serine/threonine kinase inhibitor, kills p53-deficient cells more efficiently than their p53-proficient counterparts, in vitro. Similar observations were ob...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید